Oral plasma kallikrein inhibitor BCX7353 for treatment of hereditary angioedema

Jacqueline R. Hwang, Gloria Hwang, Ansh Johri, Timothy Craig

Research output: Contribution to journalArticle

Abstract

Hereditary angioedema (HAE) is rare disorder caused by a SERPING1 gene mutation that triggers severe swelling of the skin and upper airway. Treatment options for HAE with deficient and dysfunctional C1-inhibitor are expanding to include small-molecule drugs that inhibit protein interactions in the kallikrein-kinin system. Discovered by BioCryst Pharmaceuticals, BCX7353 is a synthetic, once-daily, small molecule drug that can be taken as an oral capsule to treat HAE attacks and for prophylaxis. This article will summarize recent and current BCX7353 clinical trials. Overall, results indicate BCX7353 is a promising form of therapy with a rapid 1 h onset of action, long duration of action, and acceptable tolerance.

Original languageEnglish (US)
Pages (from-to)1439-1444
Number of pages6
JournalImmunotherapy
Volume11
Issue number17
DOIs
StatePublished - Jan 1 2019

Fingerprint

Plasma Kallikrein
Hereditary Angioedemas
Pharmaceutical Preparations
Kallikrein-Kinin System
Capsules
Clinical Trials
Skin
Mutation
Genes
Proteins
Therapeutics

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Immunology
  • Oncology

Cite this

Hwang, Jacqueline R. ; Hwang, Gloria ; Johri, Ansh ; Craig, Timothy. / Oral plasma kallikrein inhibitor BCX7353 for treatment of hereditary angioedema. In: Immunotherapy. 2019 ; Vol. 11, No. 17. pp. 1439-1444.
@article{e0b18890970d41129506e4ee09474d6f,
title = "Oral plasma kallikrein inhibitor BCX7353 for treatment of hereditary angioedema",
abstract = "Hereditary angioedema (HAE) is rare disorder caused by a SERPING1 gene mutation that triggers severe swelling of the skin and upper airway. Treatment options for HAE with deficient and dysfunctional C1-inhibitor are expanding to include small-molecule drugs that inhibit protein interactions in the kallikrein-kinin system. Discovered by BioCryst Pharmaceuticals, BCX7353 is a synthetic, once-daily, small molecule drug that can be taken as an oral capsule to treat HAE attacks and for prophylaxis. This article will summarize recent and current BCX7353 clinical trials. Overall, results indicate BCX7353 is a promising form of therapy with a rapid 1 h onset of action, long duration of action, and acceptable tolerance.",
author = "Hwang, {Jacqueline R.} and Gloria Hwang and Ansh Johri and Timothy Craig",
year = "2019",
month = "1",
day = "1",
doi = "10.2217/imt-2019-0128",
language = "English (US)",
volume = "11",
pages = "1439--1444",
journal = "Immunotherapy",
issn = "1750-743X",
publisher = "Future Medicine Ltd.",
number = "17",

}

Oral plasma kallikrein inhibitor BCX7353 for treatment of hereditary angioedema. / Hwang, Jacqueline R.; Hwang, Gloria; Johri, Ansh; Craig, Timothy.

In: Immunotherapy, Vol. 11, No. 17, 01.01.2019, p. 1439-1444.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Oral plasma kallikrein inhibitor BCX7353 for treatment of hereditary angioedema

AU - Hwang, Jacqueline R.

AU - Hwang, Gloria

AU - Johri, Ansh

AU - Craig, Timothy

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Hereditary angioedema (HAE) is rare disorder caused by a SERPING1 gene mutation that triggers severe swelling of the skin and upper airway. Treatment options for HAE with deficient and dysfunctional C1-inhibitor are expanding to include small-molecule drugs that inhibit protein interactions in the kallikrein-kinin system. Discovered by BioCryst Pharmaceuticals, BCX7353 is a synthetic, once-daily, small molecule drug that can be taken as an oral capsule to treat HAE attacks and for prophylaxis. This article will summarize recent and current BCX7353 clinical trials. Overall, results indicate BCX7353 is a promising form of therapy with a rapid 1 h onset of action, long duration of action, and acceptable tolerance.

AB - Hereditary angioedema (HAE) is rare disorder caused by a SERPING1 gene mutation that triggers severe swelling of the skin and upper airway. Treatment options for HAE with deficient and dysfunctional C1-inhibitor are expanding to include small-molecule drugs that inhibit protein interactions in the kallikrein-kinin system. Discovered by BioCryst Pharmaceuticals, BCX7353 is a synthetic, once-daily, small molecule drug that can be taken as an oral capsule to treat HAE attacks and for prophylaxis. This article will summarize recent and current BCX7353 clinical trials. Overall, results indicate BCX7353 is a promising form of therapy with a rapid 1 h onset of action, long duration of action, and acceptable tolerance.

UR - http://www.scopus.com/inward/record.url?scp=85076449690&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85076449690&partnerID=8YFLogxK

U2 - 10.2217/imt-2019-0128

DO - 10.2217/imt-2019-0128

M3 - Article

C2 - 31635497

AN - SCOPUS:85076449690

VL - 11

SP - 1439

EP - 1444

JO - Immunotherapy

JF - Immunotherapy

SN - 1750-743X

IS - 17

ER -